KPV Frequently Asked Questions

KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH). Despite being a small fragment, KPV retains significant anti-inflammatory activity attributed to the parent hormone. Peptides Pharma KPV is formulated at >99% purity in a lyophilized vial.

Research suggests KPV exerts anti-inflammatory effects by inhibiting the NF-kB signalling pathway, a master regulator of inflammatory gene expression. Studies indicate it can enter cells and directly interact with inflammatory signalling cascades, reducing pro-inflammatory cytokine production. Unlike full-length alpha-MSH, KPV does not significantly affect melanogenesis at typical research concentrations.

KPV is studied in research related to inflammatory bowel disease models, colitis, gut mucosal healing, wound healing, skin inflammation, and immune modulation. Its ability to target NF-kB makes it relevant across a broad range of inflammatory research contexts.

Peptides Pharma KPV is manufactured to >99% purity in GMP-certified, ISO 7 cleanroom facilities. Each batch is tested by independent laboratories using HPLC and mass spectrometry. Certificates of Analysis are available for every batch.

Lyophilized KPV should be stored at -20°C for long-term storage or at 2-8°C for short-term use. Keep away from direct light and moisture. Once reconstituted, store the solution at 2-8°C and use within 28 days.

Reconstitute KPV by slowly adding bacteriostatic water along the inside wall of the vial. Allow the lyophilized powder to dissolve gently — do not shake. Choose the reconstitution volume based on the desired concentration for your specific research protocol.

Reconstituted KPV stored at 2-8°C in bacteriostatic water is typically stable for up to 28 days. Always use sterile technique when accessing the vial to prevent contamination and maintain solution quality.

Yes. Peptides Pharma KPV is supplied strictly for laboratory and research use. It is not approved as a medicine and is not intended for human therapeutic application. Researchers should follow all applicable regulatory and institutional guidelines.

KPV is sometimes studied alongside BPC-157 in gut health and recovery research, as both peptides exhibit tissue-protective properties through different mechanisms — KPV via NF-kB inhibition and BPC-157 via nitric oxide and growth factor modulation. Researchers should base combination protocols on published literature.

Peptides Pharma ships KPV in lyophilized form with appropriate cold-chain packaging to ensure stability during transit. All orders include tracked delivery so researchers can monitor shipment progress and receive the product in optimal condition.